ADC Therapeutics SA (ADCT) Tops Q4 EPS by 47c

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.39), $0.47 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $17 million versus the consensus estimate of $16.46 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• Hitachi Ltd. (HIT) Misses Q2 EPS by 7c